



NASCPC NEWSLETTER

The National AIDS and STIs Control Programme
www.nascpc.gov.ng

February 2021

NATIONAL DATA REPOSITORY (NDR)

The National Data Repository (NDR) is a Federal Ministry of Health project supported by PEPFAR.



The National Data Repository (NDR) is a repository of de-identified patient level data collected from health facilities across the country. Patient data are collected at the facilities, entered directly into Electronic Medical Records (EMR) system, or transcribed from paper-based records into various EMRs and then the data is sent to the NDR server. The NDR currently contains longitudinal patient treatment history beginning from enrollment into HIV care to the last date of clinic visit. The system provides support for real time monitoring of disease programs in Nigeria, monitoring Nigeria's progress towards achieving UNAIDS 95-95-95 goal. The NDR is able to generate data required for public health response and interventions, monitoring HIV recent infections, sentinel events for HIV case-based surveillance and data for care. The data presented were generated from the NDR.



3,052,904

Number of individuals ever enrolled in care



224,871

Number of Patients who visited within the month



2,261


Registered Facilities on the NDR
Treatment facilities reported for January: 1,358
SURGE facilities reported for January: 430

A downward trend in the number of patients who visited during the month (238,560 in Dec 2020 when compared to 224,871 in Jan 2021) was observed. This may be as a result of the multidrug dispensing model among other differential Service Delivery(DSD) Models adopted. This is also key to understanding the effects of barriers to accessing health services among the general population e.g. COVID-19 pandemic. Additionally, it highlights the significant gap (903 registered facilities on the NDR did not report on the NDR in January 2021) in the number of facilities that reported on the NDR. This gap results in incomplete data for efficient and effective decision making, clinical interventions, and programmatic decisions.

SECOND 90: PATIENTS IN HIV CARE AND TREATMENT




The chart below highlights the number of patients newly initiated on treatment. It measures the ongoing scale up and uptake of ART programs. The dis-aggregation of newly initiated on ART clients by age/sex is vital to understand the percentage of new ART initiations coming from priority populations.



Patients newly initiated on treatment (N = 33,440)

The chart below measures the ongoing scale-up & uptake of ART and continuity of treatment in ART programs and assesses progress towards coverage of ART for all eligible HIV-positive individuals. Dis-aggregation by age and sex can help better understand which populations are at epidemic control and which populations are lagging behind.



Patients currently receiving treatment (N = 1,336,549)

SECOND 90: PATIENTS IN HIV CARE AND TREATMENT



The table below clearly depicts greater LTFU (36,227) and exits (LTFU+Death+Transferred Out – total of 36,721) than the TX_NEW (33,400). This provides a better understanding of the fluctuations in the active ART patient population over time.


Retention of PLHIV in the treatment program is essential in achieving the 95:95:95 goal. Progress has been made but there is a downward trend in the Active (Retention rate) as shown in the graph below

INDICATORS SUMMARY

Patient records uploaded as at the end of January 2021

Indicators	Female (%)	Male (%)	Total
Treatment New	19,159 (57.0%)	14,281 (43.0%)	33,440 (100.0)
Treatment Current	881,846 (66.0%)	454,703 (34.0%)	1,336,549 (100.0)
LTFU	24,352 (67.2%)	11,875 (32.8%)	36,227 (100.0)
Death	99 (64.7%)	54 (35.3%)	153(100.0)
Transferred Out	244 (71.6%)	97 (28.4%)	341(100.0)

MONTHLY RETENTION ANALYSIS OF HIV PATIENTS RECEIVING ART FOR JAN, 2020-JAN, 2021



This graph presents monthly % retention of patients who were followed up from January 1st 2020 and those who entered the treatment program monthly (newly started on ART, transferred -in and re-initiated on ART) from January 2020 through January 2021.

THIRD 90: VIRAL SUPPRESSION AND QUALITY OF CARE







The chart below shows a significant gap of 19,240 (only 27,846 out of 47,086 eligible for VL clients at 6 months were tested for Viral load)

The chart below highlights a major gap of 30,673 (only 284,453 out of 315,126 eligible for VL clients were tested for Viral load).

DTG is highly recommended for adults on ART for better health outcomes and quality of life. The chart below illustrates that a remarkable percentage of adults (95%) are on DTG while a minimal percentage of 5% are not on DTG.

The chart shows that 64% of the pediatric (6-14 years) are on DTG while 14% are on other first line and 22% on 2nd line regimen.




KEY: *TDF - Tenofovir *3TC - Lamivudine*AZT - Zidovudine *NVP - Nevirapine *DTG - Dolutegravir * VL - Viral Load LTFU-Lost To Follow Up

TREATMENT CURRENT, VIRAL LOAD COVERAGE AND VL SUPPRESSION



Treatment Current, Viral Load Coverage and VL Suppression: January 2021

The chart below shows the clients on ART, Viral load coverage, and Viral load suppression among the ART clients.




FACILITY REPORTING RATE AND NUMBER OF PATIENTS LOST TO FOLLOW UP



Facility Reporting Rate and Number of Patients Lost to Follow Up : January 2021

The chart below shows the proportion of facilities that reported on the NDR as against the number that are expected to report on within the reporting period of Jan 2021. Additionally, it shows the number of LTFU clients in Jan 2021 across the various States. Timely and complete reports are essential attributes of the quality of data submitted across Health Facilities and by extension quality of decision making



Data source: NDR
Data used was downloaded from Nigeria National Data Repository on 06/02/2021

TREATMENT TREND BY STATE



The table below highlights the treatment trend analysis across the various states for the respective period under review.

Trend of Treatment Current					
States	Jan-Mar 20 (Currently on Treatment)	Apr-Jun 20 (Currently on Treatment)	Jul-Sept 20 (Currently on Treatment)	Oct-Dec 20 (Currently on Treatment)	January 21 (Currently on Treatment)
Abia	438	774	1074	1,329	356
Adamawa	23,090	23,709	27,995	31,118	31,118
Akwa-Ibom	101,325	116,965	146,666	167,488	171,990
Anambra	21,204	21,206	46,700	74,285	19,217
Bauchi	17,462	16,288	17,607	19,863	21,395
Bayelsa	5,627	6,107	8,498	9,696	9,780
Benue	156,579	160,626	171,434	178,915	196,731
Borno	9,821	10,071	10,718	11,162	11,273
Cross-River	38,934	43,282	46,820	49,556	52,005
Delta	20,673	26,234	32,779	39,598	45,737
Ebonyi	7,093	7,107	7,254	7,351	8,038
Edo	15,852	16,004	16,145	16,295	19,600
Ekiti	3,365	3,451	3,543	3,738	4,124
Enugu	22,893	25,035	28,783	33,465	40,052
FCT	44,901	48,777	57,007	63,514	70,656
Gombe	21,284	22,263	24,675	25,856	27,773
Imo	16,945	19,104	21,162	23,324	32,375
Jigawa	6,545	6,443	6,582	6,621	7,814
Kaduna	48,920	51,065	52,050	53,394	58,594
Kano	29,542	25,659	27,580	28,817	27,502
Katsina	7,811	8,422	8,718	9,052	10,636
Kebbi	4,625	5,023	5,793	6,166	8,946
Kogi	18,250	18,952	19,939	20,154	22,488
Kwara	7,453	6,966	7,496	7,617	8,329
Lagos	70,067	76,178	88,636	93,868	90,200
Nasarawa	42,780	44,865	50,057	52,771	56,732
Niger	18,852	20,586	25,298	27,897	29,292
Ogun	12,317	12,417	13,120	13,685	16,936
Ondo	10,428	10,673	11,010	11,576	12,341
Osun	4,984	4,968	5,099	5,315	6,908
Oyo	15,827	16,499	17,292	17,671	22,146
Plateau	38,304	38,331	40,740	41,143	44,693
Rivers	61,291	75,346	99,568	107,627	131,888
Sokoto	4,434	5,533	6,217	6,256	7,261
Taraba	4,070	7,469	13,820	15,490	2,076
Yobe	4,242	4,301	4,435	4,576	4,906
Zamfara	2,601	2,949	3,199	3,353	4,560


Data source: NDR
Data used was downloaded from Nigeria National Data Repository on 06/02/2021

SURGE




The national prevalence of HIV is 1.4% (1.9 million people infected) and varies widely between 0.3% to 5.5% among states. Ten states with different saturation and unmet need account for about 70% of the burden. To reach epidemic control, Nigeria has scaled up evidence-based interventions tailored toward case-finding, linkage to care with immediate ART initiation, and improved viral suppression.

Case finding and Testing Yield in January 2021



ART Initiation and Linkage to Treatment in January 2021



HTS_TST_POS: Number of individuals who received HIV Testing Services (HTS) and received their test results.

Treatment NEW: Number of adults and children newly enrolled on antiretroviral therapy (ART).

Yield: Percentage of Positive test results from testing program.

Linkage %: Percentage of HIV positive that linked for treatment initiation.

*TX_CURR - Treatment Current

Data source: NDR
Data used was downloaded from Nigeria National Data Repository on 06/02/2021



Viral Load Analysis for January 2021



An analysis of the data for January 2021 showed that, the number of samples tested were below the number received. Similarly, the number of results dispatched is lower than the number of tests conducted. Nonetheless, fewer samples were rejected (35) in January, 2021 when compared to samples rejected (89) in January, 2020 even though more samples were received (80,756), tested (73,873) and dispatched(44,674) in January, 2021. When compared to samples received (68548), tested (60,515) and dispatched(38591) in January, 2020.


EID Analysis for January 2021



An analysis of the data for January 2021 showed that the number of samples tested was below the number received. Although the number of samples rejected is comparatively small, it is still important to address this because those children whose samples were not tested on time or rejected will have delayed diagnosis and treatment if need be.

Data as reported on the National Laboratory Information Management System (LIMS) Dashboard
 VL=Viral Load
 EID=Early Infant Diagnosis

INTEGRATED BIOLOGICAL AND BEHAVIOURAL SURVEILLANCE SURVEY (IBBSS)



The goal of the Integrated Biological and Behavioural Surveillance Survey (IBBSS) is to obtain serological, behavioural and HIV service coverage data on key populations with a view to developing and expanding the HIV prevention and care services suited to the context of these population groups. The progress of the 2020 IBBSS is shown above.

The National AIDS and STIs control Program (NASCP) of the Federal Ministry of Health (FMoH) coordinates the National Health sector response on HIV/AIDS. NASCP ensures the formulation and implementation of National policies, guidelines and SOPs for Prevention, Care and Treatment of HIV infections as well as STIs and Hepatitis.